Online citations, reference lists, and bibliographies.
← Back to Search

Botulinum Toxin Type A For The Management Of Glabellar Rhytids

A. Tremaine, J. L. McCullough
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
There is an increasing demand for minimally-invasive cosmetic procedures to arrest the aging process. Botulinum toxin type A injections are the most commonly used nonsurgical cosmetic procedures in the United States. There has been research spanning over two decades dedicated to safety, efficacy, dosing, and complications of botulinum toxin type A. There are now two Food and Drug Administration (FDA) approved botulinum toxin type A options in the United States: Botox® and Dysport™, with new advances being made in the field.
This paper references
10.1097/00006534-197001000-00062
AMERICAN SOCIETY FOR AESTHETIC PLASTIC SURGERY
S. Fredricks (1970)
10.1097/PRS.0b013e31818dbfe3
A Comprehensive Review of Patient-Reported Satisfaction with Botulinum Toxin Type A for Aesthetic Procedures
S. Fagien (2008)
Complications and adverse effects: diagnosis and treatment
Hexsel D. Mazzuco (2002)
10.1111/J.1524-4725.2005.31206
Prospective, Double‐Blind, Randomized, Parallel‐Group, Dose‐Ranging Study of Botulinum Toxin Type A in Men with Glabellar Rhytids
A. Carruthers (2005)
10.1097/PRS.0b013e3181b5641b
Evaluation of Variable-Dose Treatment with a New U.S. Botulinum Toxin Type A (Dysport) for Correction of Moderate to Severe Glabellar Lines: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study
M. Kane (2009)
Toxine botulique et rides faciales: une nouvelle procédure d'injection.
C. Le Louarn (1998)
The American Society for Aesthetic Plastic Surgery . Cosmetic surgery national data bank
A Carruthers
10.1111/J.1524-4725.2007.33115.X
A Randomized, Evaluator‐Blinded, Two‐Center Study of the Safety and Effect of Volume on the Diffusion and Efficacy of Botulinum Toxin Type A in the Treatment of Lateral Orbital Rhytides
A. Carruthers (2007)
Conservation, dilution, and storage after dilution Cosmetic Use of Botulinum Toxin
M Zechmeister (2002)
Available at: http://www.galderma. com/News.asp?rub=40&Id=97
Galderma (2009)
A randomized, evaluatorblinded, two-center study of the safety and effect of volume on the diffusion and efficacy of botulinum toxin type a in the treatment of lateral orbial rhytides
A Carruthers (2007)
Combination treatment of glabellar rhytids
A Erian (1999)
10.2165/00128071-200506030-00001
Managing Adverse Events Associated with Botulinum Toxin Type A
U. Wollina (2005)
10.1016/J.SDER.2006.12.004
Complications with the use of botulinum toxin type A for cosmetic applications and hyperhidrosis.
M. A. Peña (2007)
10.1080/17429590701523752
Patient‐reported outcomes with botulinum neurotoxin type A
A. Carruthers (2007)
[Botulinum toxin and facial wrinkles: a new injection procedure].
C. Le Louarn (1998)
10.1097/01.PRS.0000076504.79727.62
Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Botulinum Toxin Type A for Patients with Glabellar Lines
J. Carruthers (2003)
10.1046/J.1524-4725.2003.29121.X
Multicenter, Double‐Blind Study of the Efficacy of Injections With Botulinum Toxin Type A Reconstituted Up to Six Consecutive Weeks Before Application
D. Hexsel (2003)
10.1016/J.JAAD.2003.11.084
A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines.
B. Ascher (2004)
10.1111/J.1524-4725.2006.32332.X
A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.
G. Monheit (2007)
10.1111/J.1524-4725.1998.TB04100.X
Botulinum Toxin Type A for Facial Rejuvenation: United States and United Kingdom Perspectives
N. Lowe (1998)
10.1001/ARCHDERM.138.4.510
Pain associated with injection of botulinum A exotoxin reconstituted using isotonic sodium chloride with and without preservative: a double-blind, randomized controlled trial.
M. Alam (2002)
10.1016/j.jaad.2009.03.049
Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study.
G. Monheit (2009)
10.1111/J.1524-4725.1992.TB03295.X
Treatment of glabellar frown lines with C. botulinum-A exotoxin.
J. Carruthers (1992)
Complications and adverse effects: diagnosis and treatment Cosmetic Use of Botulinum Toxin
D Hexsel
10.1001/ARCHDERM.140.11.1351
Effect of volume and concentration on the diffusion of botulinum exotoxin A.
T. Hsu (2004)
Technical overview of topical botulinum toxin Medicis and Revance announce agreement for development of next - gen neurotoxin . July 28 , 2009
P Modi (2008)
10.1111/J.1524-4725.2006.32327.X
Repeated botulinum toxin A injections for the treatment of lines in the upper face: a retrospective study of 4,103 treatments in 945 patients.
B. Rzany (2007)
doubleblind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application
D M Hexsel (2003)
10.1111/j.1524-4725.2009.01063.x
A Four‐Month Randomized, Double‐Blind Evaluation of the Efficacy of Botulinum Toxin Type A for the Treatment of Glabellar Lines in Women with Skin Types V and VI
P. Grimes (2009)
Patientreported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study
S Fagien (2007)
10.1097/00006534-199407000-00009
Botulinum Toxin A for Hyperkinetic Facial Lines: Results of a Double-Blind, Placebo-Controlled Study
M. Keen (1994)
Medicis and Revance announce agreement for development of next-gen neurotoxin Available at: http://www.revance.com/401-news-publications?side
Revance Therapeutics (2009)
Treatment of dynamic facial wrinkles with botulinum toxin type A (Dysport)-a pilot study
G Feller (2000)
10.1007/s00266-002-2047-1
Long-Term Prospective Follow-Up of Botulinum Toxin Treatment for Facial Rhytides
N. Bulstrode (2002)
Topical botulinum toxin type A for the treatment of moderate to severe lateral canthal lines: Preliminary safety and efficacy results of a blinded, randomized, placebo controlled trial
FP Atamoros (2009)
Safety and Tolerability of Topical Botulinum Toxin Type A in Healthy Adults
T. Jones (2009)
10.1185/03007990903028203
Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?
K. Wohlfarth (2009)
Safety and Tolerability of Topical Botulinum Toxin Type A in Healthy Adults. Montreal, Canada: Poster session presented at 69th Annual Meeting of the Society for Investigative Dermatology
T Jones (2009)
10.1007/s00266-008-9153-7
Novel Topical BoNTA (CosmeTox, Toxin Type A) Cream Used to Treat Hyperfunctional Wrinkles of the Face, Mouth, and Neck
C. Bergeret-Galley (2008)
10.1001/ARCHDERM.142.3.320
Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
B. Rzany (2006)
10.1136/bjo.82.5.528
Botulinum toxin A treatment of overactive corrugator supercilii in thyroid eye disease
J. Olver (1998)
10.1111/J.1524-4725.2006.32339.X
Dilution volume of botulinum toxin type A for the treatment of glabellar rhytides: does it matter?
A. Carruthers (2007)
Conservation, dilution, and storage after dilution
M Zechmeister (2002)
Mazzuco , Zechmeister M , et al . Complications and adverse effects : diagnosis and treatment
D. Hexsel
10.1111/J.1524-4725.2006.32326.X
Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes.
J. Carruthers (2007)
10.1067/MJD.2002.121356
A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines.
J. A. Carruthers (2002)
10.1111/j.1365-4632.2009.04071.x
An open‐label, randomized, 64‐week study repeating 10‐ and 20‐U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects
M. Kawashima (2009)
10.1097/IOP.0b013e31819946c4
High Versus Low Concentration Botulinum Toxin A for Benign Essential Blepharospasm: Does Dilution Make a Difference?
Michael H. Boyle (2009)
10.1111/j.1524-4725.2009.01158.x
Blind Multicenter Study of the Efficacy and Safety of Injections of a Commercial Preparation of Botulinum Toxin Type A Reconstituted up to 15 Days Before Injection
D. Hexsel (2009)
10.1097/01.iio.0000167239.34149.13
Complications With the Use of Botulinum Toxin
A. Klein (2005)
10.1159/000048297
Effect of Botulinum Toxin A on Facial Wrinkle Lines in Koreans
H. Lew (2002)
10.1016/S0190-9622(96)90682-9
Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique.
N. Lowe (1996)
10.1001/archfacial.2009.5
Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines.
R. Moy (2009)
Revance Announces Efficacy of Topical Botulinum Toxin Type A for the Treatment of Facial Wrinkles
Revance Therapeutics
Treatment of dynamic facial wrinkles with botulinum toxin type A (Dysport ™ )-a pilot study
G Feller (2000)
10.1007/s00415-008-0031-7
Biological activity of two botulinum toxin type A complexes (Dysport® and Botox®) in volunteers
K. Wohlfarth (2008)
10.1002/mus.21343
Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg
L. Carli (2009)
Technical overview of topical botulinum toxin Available at: http://www.transdermalcorp.com/images/Transdermal Corp-TopicalToxin-Business
P Modi (2009)
The American Society for Aesthetic Plastic Surgery Cosmetic surgery national data bank. Available at http://www.surgery.org/sites/default/ files/2008stats
(2009)
10.1111/J.1524-4725.2005.31107
Dose‐Ranging Study of Botulinum Toxin Type A in the Treatment of Glabellar Rhytids in Females
A. Carruthers (2005)
A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: assessing patients' perception of treatment outcomes.
A. Carruthers (2009)
The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment.
Mark G. Rubin (2009)
10.1002/mds.22157
Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay
M. Brin (2008)
Revance Announces Efficacy of Topical Botulinum Toxin Type A for the Treatment of Facial Wrinkles Available at: http://www.revance.com/401-news- publications?side
Revance Therapeutics (2009)
10.1016/J.JAAD.2006.07.006
Comparison of two formulations of botulinum toxin type A for the treatment of glabellar lines: a double-blind, randomized study.
Philippa L Lowe (2006)
[Botulinum toxin in the treatment of frontoglabellar and periorbital wrinkles. An initial study].
B. Ascher (1995)
Galderma . Inc . Galderma 2009 News
T Jones
10.1111/J.1524-4725.2006.32325.X
Patient-reported outcomes with botulinum toxin type A treatment of glabellar rhytids: a double-blind, randomized, placebo-controlled study.
S. Fagien (2007)
10.1111/j.1524-4725.1998.tb04095.x
Botulinum A Toxin for Glabellar Wrinkles: Dose and Response
C. Hankins (1998)
10.1016/j.jaad.2009.01.005
A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: safety and efficacy.
A. Carruthers (2009)
10.1002/mds.22336
Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double‐blind study
G. Kranz (2009)
Randomized, placebocontrolled study of a new botulinum toxin type A for treatment of glabellar lines: efficacy and safety
F Brandt (2009)
Technical overview of topical botulinum toxin
P. Modi (2009)
10.1097/WNF.0b013e3181914d0a
Neutralizing Antibodies and Secondary Therapy Failure After Treatment With Botulinum Toxin Type A: Much Ado About Nothing?
O. Lange (2009)
10.1185/030079904125003962
Safety of botulinum toxin type A: a systematic review and meta-analysis
M. Naumann (2004)
10.1111/j.1524-4725.2009.01235.x
Randomized, Placebo‐Controlled Study of a New Botulinum Toxin Type A for Treatment of Glabellar Lines: Efficacy and Safety
F. Brandt (2009)
Medicis and Revance announce agreement for development of next-gen neurotoxin
Revance Therapeutics
10.1016/J.JAAD.2006.01.019
Sterility assessment of multiple use botulinum A exotoxin vials: a prospective simulation.
M. Alam (2006)
10.1016/j.toxicon.2009.03.020
Dysport: pharmacological properties and factors that influence toxin action.
A. Pickett (2009)
Treatment of dynamic facial wrinkles with botulinum toxin type A ( Dysport TM ) - a pilot study
C LeLouarn (2000)
10.1016/S1535-1513(09)79439-1
Long-term Safety and Efficacy of a New Botulinum Toxin Type A in Treating Glabellar Lines
K. Gutowski (2011)



This paper is referenced by
Efficacy and Side Effect of Dysport for Treatment of Forehead & Glabellar Line
Mahdi Amirnia (2014)
10.1016/J.YACS.2019.02.002
Nonsurgical Periorbital Rejuvenation
Loreley D. Smith (2019)
10.1111/joor.12491
Mechanism of motor coordination of masseter and temporalis muscles for increased masticatory efficiency in mice
Tomoko Yoshimi (2017)
10.5812/aapm.9356
Central Nervous System Toxicity After Botulinum Neurotoxin Injection
Yashar Ilkhchoui (2013)
10.1016/j.fsc.2015.01.010
The role of neurotoxins in the periorbital and midfacial areas.
B. Erickson (2015)
10.1097/PSN.0000000000000121
The Dilution Confusion: Easy Dosing for Botulinum Toxins.
Julie Bass Kaplan (2016)
10.3892/mmr.2020.11501
Effects of botulinum toxin A on endometriosis-associated pain and its related mechanism
Fubo Tian (2020)
10.1097/DSS.0000000000001412
The Use of Botulinum Neurotoxin Type A in Aesthetics: Key Clinical Postulates
M. Nestor (2017)
10.1177/1754073919868762
Does Blocking Facial Feedback Via Botulinum Toxin Injections Decrease Depression? A Critical Review and Meta-Analysis
N. A. Coles (2019)
10.1093/asj/sjw282
Key Parameters for the Use of AbobotulinumtoxinA in Aesthetics: Onset and Duration
M. Nestor (2017)
10.1007/978-3-319-58756-1_12
Complications in the Cosmetic Use of Botulinum Toxin Type A: Prevention and Management
Whitney Florin (2018)
10.1007/s00266-014-0445-9
Effectiveness of Botulinum Toxin (Type-A) Administered by the Fixed-Site Dosing Approach Versus the Muscle Area Identification
Jose Guerrrerosantos (2014)
10.1007/s13671-011-0006-2
Epidemiology of Cosmetic Procedures: An Update for Dermatologists
J. Sobanko (2012)
10.1111/cxo.13117
Abobotulinum toxin A for periorbital facial rejuvenation: impact on ocular refractive parameters.
M. H. Eftekhari (2020)
Semantic Scholar Logo Some data provided by SemanticScholar